Skip to main content

Damora Therapeutics, Inc.

corporate_fare Company Profile

Damora Therapeutics, Inc.

DMRA·NASDAQ·Life Sciences·CIK 0001800315

Damora Therapeutics is a biopharmaceutical company that develops therapies for hematologic disorders. The company's pipeline includes three product candidates designed to treat myeloproliferative neoplasms ("MPNs"), which are chronic bone marrow disorders. Damora's lead product candidate is DMR-001, which targets mutant forms of the calcium binding protein calreticulin ("CALR"), known as mutCALR. Damora has licensed exclusive worldwide development and commercialization rights for DMR-001 from Paragon Therapeutics, Inc. ("Paragon") under an agreement dated October 7, 2025. Damora plans to develop DMR-001 for essential thrombocythemia ("ET"), an MPN characterized by overproduction of platelets, and myelofibrosis ("MF"), an MPN involving overproliferation of blood cells and fibrous material deposition in the bone marrow and spleen. Approximately 25% of ET cases and 35% of MF cases are caused by mutCALR. DMR-001 is designed to selectively target cells expressing mutCALR, aiming to avoid adverse effects of non-specific cytoreductive drugs. It was also designed for increased affinity, potency, and a prolonged half-life compared to other mutCALR-targeting antibodies in development. Damora also holds options to license exclusive worldwide development and commercialization rights from Paragon for two other mutCALR-targeting product candidates, DMR-002 and DMR-003. The company intends to submit an Investigational New Drug Application ("IND") or Clinical Trial Application ("CTA") for DMR-001 in mid-2026, for DMR-002 in the second half of 2026, and for DMR-003 in 2027.

Damora Therapeutics, Inc. (NASDAQ:DMRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for DMRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for DMRA spans 10-Q, 8-K, DEF 14A, 10-K.

Recent high-impact activity:

  • Damora Posts $32M Q3 Loss as R&D Spending Jumps; Cash Runs to 2H 2029
  • Damora Q3 Loss Widens to $32.0M; $528.5M Cash Funds Runway Into 2H 2029
  • Damora Therapeutics Q2 2026: $31.2M Net Loss, $540.5M Cash, DMR-001 Phase 1/1b Underway
  • Damora Launches First Clinical Trial for DMR-001, a Potential Best-in-Class Blood Cancer Therapy
  • Damora Therapeutics Extends Cash Runway to 2029 with Strong Q1 Liquidity and Pipeline Progress

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$209.84M
Diluted EPS
$3.98
Op. Cash Flow
-$6.73M
Operating Income
-$210.87M
Cash & Equivalents
$257.62M
Debt / Equity
0.00×
Shares Outstanding
1.6M sh
Source: 10-K · filed 2026-03-19 · accession 0001193125-26-115922

Short Interest & Short Volume

10.66 days to cover

FINRA reported short interest of 4,689,717 shares in DMRA as of the October 30, 2026 settlement, a 9.0% decrease from the prior period — about 10.7 days to cover at its recent average daily volume. On November 20, 2026, 52.6% of DMRA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,689,717 shares as of October 30, 2026
Change vs prior period▼ 9.0%
Days to cover10.66 at avg daily volume of 439,761
Daily short volume (FINRA facilities)52.6% of 349,429 shares on November 20, 2026
5-day average short volume42.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for DMRA, detected from its recent SEC filings.

ATM program

Post-Effective Amendment Filed · ATM Program Update

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with D →
$23.22
52-week range · as of 2026-11-04 $4.95 – $38.33
Market cap
$1.44B
Volume
643.4K (1.3× avg)
3-mo avg 502.3K
Live data · 2026-11-22 03:37 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DMRA - Latest Insights

DMRA
Nov 04, 2026, 4:06 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $22.94
Real-time Price: $23.22 info
Change: +$0.280 (+1%) info
Market Cap: $1.437B info
DMRA
Nov 04, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.94
Real-time Price: $23.22 info
Change: +$0.280 (+1%) info
Market Cap: $1.437B info
DMRA
Aug 10, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $29.54
Real-time Price: $23.22 info
Change: -$6.32 (-21%) info
Market Cap: $1.437B info
DMRA
Aug 05, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $30.02
Real-time Price: $23.22 info
Change: -$6.80 (-23%) info
Market Cap: $1.437B info
DMRA
May 12, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $23.06
Real-time Price: $23.22 info
Change: +$0.160 (+0.69%) info
Market Cap: $1.437B info
DMRA
May 04, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.98
Real-time Price: $23.22 info
Change: -$2.76 (-11%) info
Market Cap: $1.437B info
DMRA
Apr 29, 2026, 4:00 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $23.93
Real-time Price: $23.22 info
Change: -$0.710 (-3%) info
Market Cap: $1.437B info
DMRA
Mar 23, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $17.90
Real-time Price: $23.22 info
Change: +$5.32 (+30%) info
Market Cap: $1.437B info
DMRA
Mar 19, 2026, 4:00 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $19.20
Real-time Price: $23.22 info
Change: +$4.02 (+21%) info
Market Cap: $1.437B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets